415979-07-6 Usage
Uses
Used in Pharmaceutical Industry:
3-allyl-8-benzyl-3,8-diaza-bicyclo[3.2.1]octane is used as a potential active pharmaceutical ingredient for its unique molecular structure and the presence of allyl and benzyl functional groups. Its potential biological activities and reactivity make it a candidate for the development of new drugs with novel mechanisms of action.
Used in Materials Science:
3-allyl-8-benzyl-3,8-diaza-bicyclo[3.2.1]octane is used as a building block or intermediate in the synthesis of new materials with specific properties. Its unique molecular structure and reactivity can be leveraged to create materials with tailored characteristics for various applications, such as polymers, catalysts, or sensors.
Used in Organic Synthesis:
3-allyl-8-benzyl-3,8-diaza-bicyclo[3.2.1]octane is used as a versatile synthetic intermediate in organic synthesis. Its allyl and benzyl functional groups can be further modified or reacted with other molecules to create a wide range of chemical products, including pharmaceuticals, agrochemicals, or specialty chemicals.
Used in Research and Development:
3-allyl-8-benzyl-3,8-diaza-bicyclo[3.2.1]octane is used as a subject of research to explore its potential applications and properties. Scientists and researchers can study its reactivity, biological activities, and interactions with other molecules to gain insights into its potential uses and to develop new synthetic routes or applications.
Check Digit Verification of cas no
The CAS Registry Mumber 415979-07-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,1,5,9,7 and 9 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 415979-07:
(8*4)+(7*1)+(6*5)+(5*9)+(4*7)+(3*9)+(2*0)+(1*7)=176
176 % 10 = 6
So 415979-07-6 is a valid CAS Registry Number.
415979-07-6Relevant articles and documents
UROTENSIN II RECEPTOR ANTAGONISTS
-
Page/Page column 191, (2010/11/28)
The invention is directed to Urotensin II antagonists. More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating Urotensin-II mediated disorders. Pharmaceutical and veterinary compositions and methods of treating cardiovascular disorders and various other disease states or conditions using compounds of the invention are also described.
3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias
-
, (2008/06/13)
There is provided compounds of formula (I), wherein R1, R2 and Ra to Rb have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and v
